The impact of GPCR structures on pharmacology and structure-based drug design

British Journal of Pharmacology

Volumn 159, Issue 5, 2010, Pages 986-996

  Congreve, Miles ^a   Marshall, Fiona ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

Allosteric regulators; Conformation; Dimerization; Fragment screening; G protein coupled receptor; Rhodopsin; Selectivity; Structure based drug design; Virtual screening; X ray crystallography

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; ALISKIREN; AMPRENAVIR; APLAVIROC; BOCEPREVIR; CLOZAPINE; DARUNAVIR; DASATINIB; ERLOTINIB; G PROTEIN COUPLED RECEPTOR; IMATINIB; LAPATINIB; LOPINAVIR; MARAVIROC; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NELFINAVIR; ODANACATIB; OLANZAPINE; OSELTAMIVIR; RHODOPSIN; RIVAROXABAN; SEROTONIN 2 AGONIST; SITAGLIPTIN; SUNITINIB; TELAPREVIR; VICRIVIROC; VORINOSTAT; XIMELAGATRAN; ZANAMIVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BINDING SITE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COGNITIVE DEFECT; CONFORMATION; DIMERIZATION; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INFLUENZA; LUNG NON SMALL CELL CANCER; MEMBRANE BINDING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SCREENING; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WEIGHT GAIN;

CRYSTALLOGRAPHY, X-RAY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 77949370572     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00476.x     Document Type: Review

References (104)

1. Albert JS, Blomberg N, Breeze AL, Brown AJH, Burrows JN, Edwards PD et al. (2007). An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes. Curr Top Med Chem 7: 1600-1629.
2. Altenbach C, Kusnetzow AK, Ernst OP, Hofmann KP, Hubbell WL (2008). High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. Proc Natl Acad Sci USA 105: 7439-7444.
3. Archer E, Maigret B, Escrieut C, Pradayrol L, Fourmy D (2003). Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol Sci 24: 36-40.
4. Baker JG, Hill SJ (2007). Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends Pharmacol Sci 28: 374-381.
5. Ballesteros J, Palczewski K (2001). G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr Opin Drug Discov Devel 4: 561-574.
6. Barril X, Hubbard RE, Morley SD (2004). Virtual screening in structure-based drug discovery. Mini Rev Med Chem 4: 779-791.
7. Barton N, Blaney FE, Garland S, Tehan B, Wall I (2006). Receptors: seven transmembrane G protein-coupled insights for drug design from structure and modeling in computer-assisted drug design. In: Mason JS, Triggle DJ, Taylor JB (eds). Comprehensive Medicinal Chemistry II, Vol. 4, Chapter 26. Elsevier Ltd: New York, pp. 1-33.
8. Blaney FE, Capelli AM, Tedesco G (2006). 7TM models in structurebased drug design ligand design for G protein-coupled receptors In: Rognan D, Mannhold R, Kubinyi H, Folkers G (eds). Methods and Principles in Medicinal Chemistry, Vol. 30, Chapter 11. Wiley-VCH Verlag GmbH and Co.KGaA: Weinham, pp. 205-239.
9. Brawley L, Shaw AM, MacDonald A (2000). Beta 1-, beta 2- and atypical beta-adrenoceptor-mediated relaxation in rat isolated aorta. Br J Pharmacol 129: 637-644.
10. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96.
11. Chen M, Cai M, McPherson D, Hruby V, Harmon CM, Yang Y (2009). Contribution of the transmembrane domain 6 of melanocortin-4 receptor to peptide [Pro5, DNal (2′)8]-gamma-MSH selectivity. Biochem Pharmacol 77: 114-124.
12. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS et al. (2007). High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318: 1258-1265.
13. Chessari G, Woodhead AJ (2009). From fragment to clinical candidate-a historical perspective. Drug Discov Today 14: 668-675.
14. Congreve M, Murray CW, Blundell TL (2005). Structural biology and drug discovery. Drug Discov Today 10: 895-907.
15. Congreve M, Chessari G, Tisi D, Woodhead AJ (2008). Recent developments in fragment-based drug discovery. J Med Chem 51: 3661-3680.
16. Daaka Y, Luttrell LM, Lefkowitz RJ (1997). Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 390: 88-91.
17. Deupi X, Dölker N, López-Rodríguez ML, Campillo M, Ballesteros JA, Pardo L (2007). Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity. Curr Top Med Chem 7: 991-998.
18. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK (2007). Beta-arrestins and cell signaling. Annu Rev Physiol 69: 483-510.
19. Engel S, Skoumbourdis AP, Childress J, Neumann S, Deschamps JR, Thomas CJ et al. (2008). A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. J Am Chem Soc 130: 5115-5123.
20. Erlanson DA, McDowell RS, O'Brien T (2004). Fragment-based drug discovery. J Med Chem 47: 3463-3482.
21. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T et al. (2009). Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5: 131-134.
22. Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K (2003). Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature 421: 127-128.
23. Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K (2004). The G protein-coupled receptor rhodopsin in the native membrane. FEBS Lett 564: 281-288.
24. Fotiadis D, Jastrzebska B, Philippsen A, Müller DJ, Palczewski K, Engel A (2006). Structure of the rhodopsin dimer: a working model for G-protein-coupled receptors. Curr Opin Struct Biol 16: 252-259.
25. Fritze O, Filipek S, Kuksa V, Palczewski K, Hofmann KP, Ernst OP (2003). Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation. Proc Natl Acad Sci USA 100: 2290-2295.
26. Galandrin S, Oligny-Longpré G, Bouvier M (2007). The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol Sci 28: 423-430.
27. Galandrin S, Oligny-Longpré G, Bonin H, Ogawa K, Galés C, Bouvier M (2008). Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the beta1-adrenergic receptor. Mol Pharmacol 74: 162-172.
28. Ghanouni P, Steenhuis JJ, Farrens DL, Kobilka BK (2001a). Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci USA 98: 5997-6002.
29. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR et al. (2001b). Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276: 24433-24436.
30. Ghose AK, Herbertz T, Pippin DA, Salvino JM, Mallamo JP (2008). Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J Med Chem 51: 5149-5171.
31. Ghosh S, Nie A, An J, Huang Z (2006). Structure-based virtual screening of chemical libraries for drug discovery. Curr Opin Chem Biol 10: 194-202.
32. Glennon RA, Dukat-Glennon M (2008). Serotonergic receptors and drugs affecting serotonergic neurotransmission. In: Lemke TL, Williams DA (eds). Foye's Principles of Medicinal Chemistry. Lippincott Williams and Wilkins: Philadelphia, PA, pp. 417-443.
33. Goudet C, Magnaghi V, Landry M, Nagy F, Gereau RW 4th, Pin JP. (2009). Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev 60: 43-56.
34. Griffith RK (2008). Adrenergic receptors and drugs affecting adrenergic neurotransmission. In: Lemke TL, Williams DA (eds). Foye's Principles of Medicinal Chemistry. Lippincott Williams and Wilkins: Philadelphia, PA, pp. 392-416.
35. Guo W, Shi L, Filizola M, Weinstein H, Javitch JA (2005). Crosstalk in G protein-coupled receptors: changes at the transmembrane homodimer interface determine activation. Proc Natl Acad Sci USA 102: 17495-17500.
36. Gurevich VV, Gurevich EV (2008). How and why do GPCRs dimerize? Trends Pharmacol Sci 29: 234-240.
37. Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E et al. (2001). The direct thrombin inhibitor melagatran and its oral prodrug H376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101: 171-181.
38. Hanson MA, Stevens RC (2009). Discovery of new GPCR biology: one receptor structure at a time. Structure 17: 8-14.
39. Hebert TE, Moffett S, Morello JP, Loisel TP, Bichet DG, Barret C et al. (1996). A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem 271: 16384-16392.
40. Hegde S, Schmidt M (2007). To market, to market 2006. Annu Rep Med Chem 42: 505-554.
41. Hibert M, Hoflack J, Trumpp-Kallmeyer S, Mouillac B, Chini B, Mahé E et al. (1999). Functional architecture of vasopressin/oxytocin receptors. J Recept Signal Transduct Res 19: 589-596.
42. Hopkins AL, Groom CR, Alex A (2004). Ligand efficiency: a useful metric for lead selection. Drug Discov Today 9: 430-431.
43. Huber T, Sakmar TP (2008). Rhodopsin's active state is frozen like a DEER in the headlights. Proc Natl Acad Sci USA 105: 7343-7344.
44. Jaakola V, Griffith MT, Hanson MA, Cherezov V, Chien EYT, Lane JR et al. (2008). The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322: 1211-1217.
45. Kenakin T (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598-611.
46. Kenakin T (2004). Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25: 186-192.
47. Keserü GM, Makara GM (2009). The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov 8: 203-212.
48. Knierim B, Hofmann KP, Gärtner W, Hubbell WL, Ernst OP (2008). Rhodopsin and 9-demethyl-retinal analog: effect of a partial agonist on displacement of transmembrane helix 6 in class A G protein-coupled receptors. J Biol Chem 283: 4967-4974.
49. Kobilka B (2007). G protein coupled receptor structure and activation. Biochim Biophys Acta 1768: 794-807.
50. Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S et al. (2008). Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 73: 789-800.
51. Kristiansen K (2004). Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 103: 21-80.
52. Kuroki T, Nagao N, Nakahara T (2008). Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 172: 199-212.
53. Lagerström MC, Schiöth HB (2008). Structural diversity of G proteincoupled receptors and significance for drug discovery. Nat Rev Drug Discov 7: 339-357.
54. Lamb TD, Pugh ENJ (2004). Dark adaptation and the retinoid cycle of vision. Prog Retin Eye Res 23: 307-380.
55. Langmead CJ, Watson J, Reavill C (2008). Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117: 232-243.
56. Lefkowitz RJ, Shenoy SK (2005). Transduction of receptor signals by beta-arrestins. Science 308: 512-517.
57. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, Engel A (2003). Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J Biol Chem 278: 21655-21662.
58. Lodowski DT, Salom D, Le Trong I, Teller DC, Ballesteros JA, Palczewski K et al. (2007). Crystal packing analysis of rhodopsin crystals. J Struct Biol 158: 455-462.
59. Lundstrom K, Wagner R, Reinhart C, Desmyter A, Cherouati N, Magnin T et al. (2006). Structural genomics on membrane proteins: comparison of more than 100 GPCRs in 3 expression systems. J Struct Funct Genomics 7: 77-91.
60. McInnes C (2007). Virtual screening strategies in drug discovery. Curr Opin Chem Biol 11: 494-502.
61. Malherbe P, Kratochwil N, Knoflach F, Zenner M, Kew JNC, Kratzeisen C et al. (2003). Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J Biol Chem 278: 8340-8347.
62. Mancia F, Hendrickson WA (2007). Expression of recombinant G-protein coupled receptors for structural biology. Mol Biosyst 3: 723-734.
63. May LT, Leach K, Sexton PM, Christopoulos A (2007). Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47: 1-51.
64. Messer WSJ (2002). The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci 19: 187-193.
65. Milligan G (2007). G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim Biophys Acta 1768: 825-835.
66. Milligan G, Smith NJ (2007). Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 28: 615-620.
67. Mittl PR, Grütter MG (2006). Opportunities for structure-based design of protease-directed drugs. Curr Opin Struct Biol 6: 769-775.
68. Nasrallah HA (2008). Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 13: 27-35.
69. Nygaard R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW (2009). Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 30: 249-259.
70. Okada T, Ernst OP, Palczewski K, Hofmann KP (2001). Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem Sci 26: 318-324.
71. Palczewski K (2006). G protein-coupled receptor rhodopsin. Annu Rev Biochem 75: 743-767.
72. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA et al. (2000). Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745.
73. Palmer TM, Poucher SM, Jacobson KA, Stiles GL (1995). 125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-ylamino] ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol Pharmacol 48: 970-974.
74. Park JH, Scheerer P, Hofmann KP, Choe H, Ernst OP (2008). Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454: 183-187.
75. Pin JP, Kniazeff J, Goudet C, Bessis AS, Liu J, Galvez T et al. (2004). The activation mechanism of class-C G-protein coupled receptors. Biol Cell 96: 335-342.
76. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD et al. (1999). Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291: 739-748.
77. Radestock S, Weil T, Renner S (2008). Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring. J Chem Inf Model 48: 1104-1117.
78. Rasmussen SGF, Choi H, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC et al. (2007). Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 450: 383-387.
79. Ridge KD, Palczewski K (2007). Visual rhodopsin sees the light: structure and mechanism of G protein signaling. J Biol Chem 282: 9297-9301.
80. Robinson DS (2007). Antipsychotics: pharmacology and clinical decision making. Prim Psychiatry 14: 23-25.
81. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS et al. (2007). GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318: 1266-1273.
82. Rouse MB, Seefeld MA, Leber JD, McNulty KC, Sun L, Miller WH et al. (2009). Aminofurazans as potent inhibitors of AKT kinase. Bioorg Med Chem Lett 19: 1508-1511.
83. Ruprecht JJ, Mielke T, Vogel R, Villa C, Schertler GFX (2004). Electron crystallography reveals the structure of metarhodopsin I. EMBO J 23: 3609-3620.
84. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe H et al. (2008). Crystal structure of opsin in its G-protein-interacting conformation. Nature 455: 497-502.
85. Schertler GF, Hargrave PA (1995). Projection structure of frog rhodopsin in two crystal forms. Proc Natl Acad Sci USA 92: 11578-11582.
86. Schertler GF, Villa C, Henderson R (1993). Projection structure of rhodopsin. Nature 362: 770-772.
87. Schulz MN, Hubbard RE (2009). Recent progress in fragment-based lead discovery. Curr Opin Pharmacol (in press).
88. Schwartz TW (1994). Locating ligand-binding sites in 7TM receptors by protein engineering. Curr Opin Biotechnol 5: 434-444.
89. Serrano-Vega MJ, Magnani F, Shibata Y, Tate CG (2008). Conformational thermostabilization of the b1-adrenergic receptor in a detergent-resistant form. Proc Natl Acad Sci USA 105: 877-882.
90. Shukla AK, Sun J, Lefkowitz RJ (2008). Crystallizing thinking about the beta2-adrenergic receptor. Mol Pharmacol 73: 1333-1338.
91. Simonyi A, Schachtman TR, Christoffersen GR (2005). The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect 18: 353-361.
92. Vogel R, Siebert F (2001). Conformations of the active and inactive states of opsin. J Biol Chem 276: 38487-38493.
93. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B et al. (1993). Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418-423.
94. Wacker DA, Miller KJ (2008). Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Curr Opin Drug Discov Devel 11: 438-445.
95. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R et al. (2008). Structure of a beta(1)-adrenergic G-protein-coupled receptor. Nature 454: 486-491.
96. Weis WI, Kobilka BK (2008). Structural insights into G-protein-coupled receptor activation. Curr Opin Struct Biol 18: 734-740.
97. Wells JA, McClendon CL (2007). Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450: 1001-1009.
98. Wess J (1993). Mutational analysis of muscarinic acetylcholine receptors: structural basis of ligand/receptor/G protein interactions. Life Sci 53: 1447-1463.
99. Wiener MC (2004). A pedestrian guide to membrane protein crystallization. Methods 34: 364-372.
100. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S et al. (2007). A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci USA 104: 16657-16662.
101. Wong RSY, Bodart V, Metz M, Labrecque J, Bridger G, Fricker SP (2008). Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol Pharmacol 74: 1485-1495.
102. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH et al. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
103. Zimmermann J, Caravatti G, Mett H, Meyer T, Müller M, Lydon NB et al. (1996). Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm (Weinheim) 329: 371-376.
104. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB (1997). Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives. Bioorg Med Chem Lett 7: 187-192.